Cargando…

Independent Prognostic Value of Intratumoral Heterogeneity and Immune Response Features by Automated Digital Immunohistochemistry Analysis in Early Hormone Receptor-Positive Breast Carcinoma

Immunohistochemistry (IHC) for ER, PR, HER2, and Ki67 is used to predict outcome and therapy response in breast cancer patients. The current IHC assessment, visual or digital, is based mostly on global biomarker expression levels in the tissue sample. In our study, we explored the prognostic value o...

Descripción completa

Detalles Bibliográficos
Autores principales: Zilenaite, Dovile, Rasmusson, Allan, Augulis, Renaldas, Besusparis, Justinas, Laurinaviciene, Aida, Plancoulaine, Benoit, Ostapenko, Valerijus, Laurinavicius, Arvydas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308549/
https://www.ncbi.nlm.nih.gov/pubmed/32612954
http://dx.doi.org/10.3389/fonc.2020.00950
_version_ 1783549013956493312
author Zilenaite, Dovile
Rasmusson, Allan
Augulis, Renaldas
Besusparis, Justinas
Laurinaviciene, Aida
Plancoulaine, Benoit
Ostapenko, Valerijus
Laurinavicius, Arvydas
author_facet Zilenaite, Dovile
Rasmusson, Allan
Augulis, Renaldas
Besusparis, Justinas
Laurinaviciene, Aida
Plancoulaine, Benoit
Ostapenko, Valerijus
Laurinavicius, Arvydas
author_sort Zilenaite, Dovile
collection PubMed
description Immunohistochemistry (IHC) for ER, PR, HER2, and Ki67 is used to predict outcome and therapy response in breast cancer patients. The current IHC assessment, visual or digital, is based mostly on global biomarker expression levels in the tissue sample. In our study, we explored the prognostic value of digital image analysis of conventional breast cancer IHC biomarkers supplemented with their intratumoral heterogeneity and tissue immune response indicators. Surgically excised tumor samples from 101 female patients with hormone receptor-positive breast cancer (HRBC) were stained for ER, PR, HER2, Ki67, SATB1, CD8, and scanned at 20x. Digital image analysis was performed using the HALO™ platform. Subsequently, hexagonal tiling was used to compute intratumoral heterogeneity indicators for ER, PR and Ki67 expression. Multiple Cox regression analysis revealed three independent predictors of the patient's overall survival: Haralick's texture entropy of PR (HR = 0.19, p = 0.0005), Ki67 Ashman's D bimodality (HR = 3.0, p = 0.01), and CD8+SATB1+ cell density in tumor tissue (HR = 0.32, p = 0.02). Remarkably, the PR and Ki67 intratumoral heterogeneity indicators were prognostically more informative than the rates of their expression. In particular, a distinct non-linear relationship between the rate of PR expression and its intratumoral heterogeneity was observed and revealed a non-linear prognostic effect of PR expression. The independent prognostic significance of CD8+SATB1+ cells infiltrating the tumor could indicate their role in anti-tumor immunity. In conclusion, we suggest that prognostic modeling, based entirely on the computational image-based IHC biomarkers, is possible in HRBC patients. The intratumoral heterogeneity and immune response indicators outperformed both conventional breast cancer IHC and clinicopathological variables while markedly increasing the power of the model.
format Online
Article
Text
id pubmed-7308549
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-73085492020-06-30 Independent Prognostic Value of Intratumoral Heterogeneity and Immune Response Features by Automated Digital Immunohistochemistry Analysis in Early Hormone Receptor-Positive Breast Carcinoma Zilenaite, Dovile Rasmusson, Allan Augulis, Renaldas Besusparis, Justinas Laurinaviciene, Aida Plancoulaine, Benoit Ostapenko, Valerijus Laurinavicius, Arvydas Front Oncol Oncology Immunohistochemistry (IHC) for ER, PR, HER2, and Ki67 is used to predict outcome and therapy response in breast cancer patients. The current IHC assessment, visual or digital, is based mostly on global biomarker expression levels in the tissue sample. In our study, we explored the prognostic value of digital image analysis of conventional breast cancer IHC biomarkers supplemented with their intratumoral heterogeneity and tissue immune response indicators. Surgically excised tumor samples from 101 female patients with hormone receptor-positive breast cancer (HRBC) were stained for ER, PR, HER2, Ki67, SATB1, CD8, and scanned at 20x. Digital image analysis was performed using the HALO™ platform. Subsequently, hexagonal tiling was used to compute intratumoral heterogeneity indicators for ER, PR and Ki67 expression. Multiple Cox regression analysis revealed three independent predictors of the patient's overall survival: Haralick's texture entropy of PR (HR = 0.19, p = 0.0005), Ki67 Ashman's D bimodality (HR = 3.0, p = 0.01), and CD8+SATB1+ cell density in tumor tissue (HR = 0.32, p = 0.02). Remarkably, the PR and Ki67 intratumoral heterogeneity indicators were prognostically more informative than the rates of their expression. In particular, a distinct non-linear relationship between the rate of PR expression and its intratumoral heterogeneity was observed and revealed a non-linear prognostic effect of PR expression. The independent prognostic significance of CD8+SATB1+ cells infiltrating the tumor could indicate their role in anti-tumor immunity. In conclusion, we suggest that prognostic modeling, based entirely on the computational image-based IHC biomarkers, is possible in HRBC patients. The intratumoral heterogeneity and immune response indicators outperformed both conventional breast cancer IHC and clinicopathological variables while markedly increasing the power of the model. Frontiers Media S.A. 2020-06-16 /pmc/articles/PMC7308549/ /pubmed/32612954 http://dx.doi.org/10.3389/fonc.2020.00950 Text en Copyright © 2020 Zilenaite, Rasmusson, Augulis, Besusparis, Laurinaviciene, Plancoulaine, Ostapenko and Laurinavicius. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zilenaite, Dovile
Rasmusson, Allan
Augulis, Renaldas
Besusparis, Justinas
Laurinaviciene, Aida
Plancoulaine, Benoit
Ostapenko, Valerijus
Laurinavicius, Arvydas
Independent Prognostic Value of Intratumoral Heterogeneity and Immune Response Features by Automated Digital Immunohistochemistry Analysis in Early Hormone Receptor-Positive Breast Carcinoma
title Independent Prognostic Value of Intratumoral Heterogeneity and Immune Response Features by Automated Digital Immunohistochemistry Analysis in Early Hormone Receptor-Positive Breast Carcinoma
title_full Independent Prognostic Value of Intratumoral Heterogeneity and Immune Response Features by Automated Digital Immunohistochemistry Analysis in Early Hormone Receptor-Positive Breast Carcinoma
title_fullStr Independent Prognostic Value of Intratumoral Heterogeneity and Immune Response Features by Automated Digital Immunohistochemistry Analysis in Early Hormone Receptor-Positive Breast Carcinoma
title_full_unstemmed Independent Prognostic Value of Intratumoral Heterogeneity and Immune Response Features by Automated Digital Immunohistochemistry Analysis in Early Hormone Receptor-Positive Breast Carcinoma
title_short Independent Prognostic Value of Intratumoral Heterogeneity and Immune Response Features by Automated Digital Immunohistochemistry Analysis in Early Hormone Receptor-Positive Breast Carcinoma
title_sort independent prognostic value of intratumoral heterogeneity and immune response features by automated digital immunohistochemistry analysis in early hormone receptor-positive breast carcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308549/
https://www.ncbi.nlm.nih.gov/pubmed/32612954
http://dx.doi.org/10.3389/fonc.2020.00950
work_keys_str_mv AT zilenaitedovile independentprognosticvalueofintratumoralheterogeneityandimmuneresponsefeaturesbyautomateddigitalimmunohistochemistryanalysisinearlyhormonereceptorpositivebreastcarcinoma
AT rasmussonallan independentprognosticvalueofintratumoralheterogeneityandimmuneresponsefeaturesbyautomateddigitalimmunohistochemistryanalysisinearlyhormonereceptorpositivebreastcarcinoma
AT augulisrenaldas independentprognosticvalueofintratumoralheterogeneityandimmuneresponsefeaturesbyautomateddigitalimmunohistochemistryanalysisinearlyhormonereceptorpositivebreastcarcinoma
AT besusparisjustinas independentprognosticvalueofintratumoralheterogeneityandimmuneresponsefeaturesbyautomateddigitalimmunohistochemistryanalysisinearlyhormonereceptorpositivebreastcarcinoma
AT laurinavicieneaida independentprognosticvalueofintratumoralheterogeneityandimmuneresponsefeaturesbyautomateddigitalimmunohistochemistryanalysisinearlyhormonereceptorpositivebreastcarcinoma
AT plancoulainebenoit independentprognosticvalueofintratumoralheterogeneityandimmuneresponsefeaturesbyautomateddigitalimmunohistochemistryanalysisinearlyhormonereceptorpositivebreastcarcinoma
AT ostapenkovalerijus independentprognosticvalueofintratumoralheterogeneityandimmuneresponsefeaturesbyautomateddigitalimmunohistochemistryanalysisinearlyhormonereceptorpositivebreastcarcinoma
AT laurinaviciusarvydas independentprognosticvalueofintratumoralheterogeneityandimmuneresponsefeaturesbyautomateddigitalimmunohistochemistryanalysisinearlyhormonereceptorpositivebreastcarcinoma